ALK and non-small cell lung carcinoma: For example, aberrantly activations of ALK was found in approximately 4% of NSCLC tumors, and chromosomal rearrangement of ROS1 has been identified in approximately 1% of NSCLC patients (Wong et al., 2009; Gainor and Shaw, 2013).